OncoMatch/Clinical Trials/NCT05323201
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Is NCT05323201 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including fhB7H3.CAR-Ts and Fludarabine for hepatocellular carcinoma.
Treatment: fhB7H3.CAR-Ts · Fludarabine · Cyclophosphamide — This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: CD276 positive expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
has received chemotherapy/radiotherapy within the past 4 weeks
Cannot have received: radiation therapy
has received chemotherapy/radiotherapy within the past 4 weeks
Cannot have received: cellular immunotherapy
history of cellular immunotherapy
Cannot have received: antibody therapy
history of ... antibody therapy
Cannot have received: systemic hormone therapy
receiving systemic hormone therapy
Lab requirements
Blood counts
white blood cell count≥ 2.5 × 10^9 / L; hemoglobin≥ 9 g/dL; platelet count≥ 50 × 10^9 / L; lymphocyte proportion≥ 15 %
Kidney function
Serum creatinine< 220μmol/L
Liver function
Child-Pugh A, B grade; ALT and AST≤ 5 × ULN; ALB≥ 30 g/L; Total bilirubin≤ 2.5 × ULN
Cardiac function
Left ventricular ejection fraction≥ 40%; Indoor oxygen saturation ≥ 95 %
Child-Pugh A, B grade. ALT and AST≤ 5 × ULN; ALB≥ 30 g/L； Total bilirubin≤ 2.5 × ULN； Serum creatinine< 220μmol/L; Indoor oxygen saturation ≥ 95 %; Left ventricular ejection fraction≥ 40%; white blood cell count≥ 2.5 × 10^9 / L; hemoglobin≥ 9 g/dL; platelet count≥ 50 × 10^9 / L; lymphocyte proportion≥ 15 %
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05323201 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiation therapy, cellular immunotherapy disqualifies patients from enrollment.
Does this trial require CD276?
Yes, CD276 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages